TG Therapeutics (TGTX) Stock Looks Below Fair Value on Earnings
TG Therapeutics has delivered a strong share price run over the past three years, yet the stock still screens as undervalued on earnings-based multiples and only a mixed verdict on the broader valuation checks.
- Over the past three years, TG Therapeutics has returned 184.5% to shareholders, which puts extra focus on whether the current valuation leaves enough room for error.
- Future revenue growth from its existing treatments can support the current price. However, execution risks around competition and ongoing development spend may limit how much investors are willing to pay for that growth.
- The company scores 4 out of 6 on our valuation checks, which points to a mixed picture rather than a clear bargain or clear overvaluation. You can see the detail of that score at 4 out of 6.
The issue now is whether TG Therapeutics' recent gains and current price around US$56.04 still offer an appealing entry point on valuation grounds.
Is TG Therapeutics Still Cheap on Earnings?
The P/E ratio is a useful cross check for TG Therapeutics because the company is now generating positive earnings that can anchor the multiple. At the current share price, TG Therapeutics trades on a P/E of about 17.2x, which is very close to the broader biotech industry average of 16.9x and below the peer group average of 22.2x.
On Simply Wall St’s fair P/E estimate of around 24.1x, which takes into account factors such as the company’s growth profile, margins, scale and risk, TG Therapeutics screens at a discount to what investors might typically pay for similar earnings. The gap between the current 17.2x and the fair 24.1x suggests the market is placing a lower multiple on the stock than this framework implies.
Overall, TG Therapeutics appears undervalued on an earnings multiple basis when compared with its tailored fair P/E estimate.
See what the numbers say about this price — find out in our valuation breakdown.
The TG Therapeutics Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for TG Therapeutics sit on the Community page and connect the valuation puzzle above with clear, testable assumptions about the company’s future growth, margins and earnings. Each Narrative ties a specific fair value estimate to a particular story about TG Therapeutics' potential catalysts and risks, so you can track over time which version of events appears to be unfolding relative to the current share price.
Community views on TG Therapeutics sit on opposite ends of the spectrum, with one side focused on upside from BRIUMVI and the other fixated on concentration and pricing risk.
Bull case: 32% undervalued
"Massive first-mover advantages in patient and provider engagement, including successful execution of broad-based patient awareness campaigns, high provider and patient satisfaction ratings, and proven brand preference, create a flywheel effect that both compresses customer acquisition costs and meaningfully enhances operational leverage..."
Read the full Bull Case to see why TG Therapeutics could be undervalued
Bear case: 180% overvalued
"The heavy reliance on BRIUMVI for revenue, combined with a narrow commercial portfolio and slow pipeline progression, leaves TG Therapeutics extremely exposed to competitive threats from established branded IV and newer subcutaneous options, which may lead to market share losses and declining top-line revenues as the anti-CD20 class matures..."
Read the full Bear Case to see why TG Therapeutics could be overvalued
Do you think there's more to the story for TG Therapeutics? Head over to our Community to see what others are saying!
The Bottom Line
For TG Therapeutics, the key takeaway is that the stock still screens as undervalued on earnings multiples, but the broader checks point to a more balanced picture rather than a clear mispricing. The crux is whether revenue and margin progress from the existing portfolio, particularly BRIUMVI, can be delivered with enough consistency to convince the market to pay closer to that tailored P/E level. What matters most from here is whether execution keeps pace with expectations, or whether competitive and concentration risks end up justifying the current discount as a value trap rather than an opportunity.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com